DRI Healthcare Trust (DHT-UN) Q1 2025 earnings summary

Executive summary

• Internalization of management completed or agreed, with a $49M payment, expected to save $200M over 10 years, improve governance, and align interests with unitholders.

• Achieved strong Q1 2025 portfolio performance, with the second highest quarterly cash receipts and adjusted EBITDA since IPO.

• Reactivated/activated normal course issuer bid (NCIB) to repurchase up to 3,148,536 units, capitalizing on undervaluation.

• Leadership transition: Gary Collins to become Executive Chairman, Ali Hedayat to assume full-time CEO role.

• Portfolio assets, including growth and legacy assets, are performing as anticipated or better.

Financial highlights

• Q1 2025 total cash receipts: $62M, down 2% year-over-year, but up 39% sequentially from Q4 2024.

• Total income: $44M, up 5% year-over-year.

• Adjusted EBITDA: $51.7M (83% margin), down 7% year-over-year; would be $55.6M (90% margin) excluding $3.9M non-recurring internalization costs.

• Adjusted cash earnings per unit: $0.43 for Q1; $2.13 for trailing 12 months.

• Cash and equivalents: $55.7M; royalty receivables: $45M; credit availability: $312.5M as of March 31, 2025.

Outlook and guidance

• Internalization projected to save $200M over 10 years, with no further performance fees payable.

• Quarterly distribution to remain at $0.10 per unit; target payout 20%-30% of free cash flow.

• Robust pipeline with over $3B in potential deals under evaluation.

• Management focused on acquiring new royalty streams and capitalizing on pipeline opportunities.

• Expecting operating leverage and cost synergies from internalization, with costs growing slower than revenue.